Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12413703 | 0.85 | MAPT (0.48) | MAPTCHRM5ADRA2CSMN1; SMN2TP53 | |
| SCHEMBL30502329 | 0.80 | CACNA2D1 (0.39) | SMYD3 | |
| SCHEMBL2777721 | 0.78 | CHRM5 (0.55) | MAPTCHRM5ADRA2CSMN1; SMN2TP53 | |
| SCHEMBL8612552 | 0.77 | DPP4 (0.46) | SMYD3 | |
| SCHEMBL856280 | 0.77 | DPP4 (0.46) | SMYD3 | |
| SCHEMBL5891316 | 0.77 | DPP4 (0.46) | SMYD3 | |
| SCHEMBL16935735 | 0.77 | DPP4 (0.46) | SMYD3 | |
| SCHEMBL27425177 | 0.77 | CACNA2D1 (0.45) | MAPTSMN1; SMN2GAA | |
| SCHEMBL3165975 | 0.76 | CHRM5 (0.57) | MAPTCHRM5ADRA2CSMN1; SMN2TP53 | |
| SCHEMBL12506852 | 0.76 | CHRM5 (0.52) | MAPTCHRM5ADRA2CSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604601-A1 | HETERO RING COMPOUND | Astellas Pharma Inc. (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150364-A1 | HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150364-A1 | HETEROCYCLIC COMPOUND | IL2, NFATC1, ICOS | MAPT 4867/4885CHRM5 4704/4885ADRA2C 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.